<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1111521</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Mini Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Tissue-resident memory T cells in renal autoimmune diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ginsberg</surname>
<given-names>Pauline</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2146746"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Panzer</surname>
<given-names>Ulf</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/489168"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Asada</surname>
<given-names>Nariaki</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2119801"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>III. Department of Medicine, Division of Translational Immunology, University Medical Hospital Center Hamburg-Eppendorf</institution>, <addr-line>Hamburg</addr-line>, <country>Germany</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Markus Uhrberg, Heinrich Heine University of D&#xfc;sseldorf, Germany</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Geoffrey Camirand, University of Pittsburgh, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Nariaki Asada, <email xlink:href="mailto:n.asada@uke.de">n.asada@uke.de</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>23</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1111521</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>11</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>01</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Ginsberg, Panzer and Asada</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Ginsberg, Panzer and Asada</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>The discovery of tissue-resident memory T cells (T<sub>RM</sub> cells) reinterpreted the potential of human tissue-specific immunity. Following T cell receptor (TCR) activation and clonal expansion, effector T cells migrate to peripheral tissues where they remain long-term and differentiate to T<sub>RM</sub> cells after antigen clearance. This allows for prompt immunological responses upon antigen re-encounter. In addition to their protective properties in acute infections, recent studies have revealed that T<sub>RM</sub> cells might lead to aggravation of autoimmune diseases, such as lupus nephritis (LN) and anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). These diseases present as proliferative and crescentic glomerulonephritis (cGN), which is a life-threatening condition leading to end-stage renal disease (ESRD) if left untreated. A better understanding of renal T<sub>RM</sub> cells might lead to identifying new therapeutic targets for relapsing autoimmune diseases of the kidney. In this review, we summarize the current knowledge of renal T<sub>RM</sub> cells and discuss their potential pathophysiological roles in renal autoimmune diseases.</p>
</abstract>
<kwd-group>
<kwd>tissue-resident memory T cell</kwd>
<kwd>renal autoimmune disease</kwd>
<kwd>crescentic glomerulonephritis</kwd>
<kwd>lupus nephritis</kwd>
<kwd>ANCA-associated glomerulonephritis</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="68"/>
<page-count count="6"/>
<word-count count="3051"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Tissue-resident memory T cells (T<sub>RM</sub> cells) are a recently identified lymphocyte subset that resides in peripheral organs for long time periods (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). These cells have been detected and analyzed in numerous non-lymphoid tissues, especially barrier-organs. Mice studies have proven that T<sub>RM</sub> cells have superior effector functions including rapid chemokine and cytokine production. Hence, together with circulating memory T cells (e.g., effector memory T cells and central memory T cells), T<sub>RM</sub> cells are critical for efficient pathogen clearance, providing an antigen-specific immediate frontline defense in peripheral organs (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>The kidney is a non-barrier organ, but still frequently gets challenged by diverse pathogens, including bacteria, viruses, and fungi, which drive renal T<sub>RM</sub> cell generation (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1A</bold>
</xref>) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). Due to limited access, exploring precise immune cell populations of healthy human kidneys had been challenging. In the last few years, however, detailed analysis of the immune landscape in healthy renal tissue has been implemented using flow cytometry and single-cell RNA sequencing (scRNA-seq) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B17">17</xref>). In particular, the combined analysis of mRNA expression and cell surface marker <italic>via</italic> cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) has provided a completely new insight into cell heterogeneity. Consequently, CD4<sup>+</sup> and CD8<sup>+</sup> T cells with a T<sub>RM</sub> cell phenotype were identified in the healthy human kidney, representing the most abundant tissue-resident immune cell population (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>General features of T<sub>RM</sub> cells. Renal T<sub>RM</sub> cell development and phenotype. <bold>(A)</bold> As classical antigen-presenting cells (APC), dendritic cells (DCs) constantly surveil their microenvironment for pathogens and microbes. Once DCs in the kidney are activated, these cells migrate to the renal draining lymph nodes to present the processed antigen <italic>via</italic> the major histocompatibility complex (MHC) to na&#xef;ve T cells (<xref ref-type="bibr" rid="B3">3</xref>). Upon activation, na&#xef;ve T cells become effector T cells and migrate to the inflamed kidney <italic>via</italic> a chemokine gradient (<xref ref-type="bibr" rid="B4">4</xref>). While most of the effector T cells undergo apoptosis following the resolution of inflammation, a small subset of the effector T cells become T<sub>RM</sub> cells. T<sub>RM</sub> cells are the most abundant immune cell population in the healthy human kidney (<xref ref-type="bibr" rid="B5">5</xref>). <bold>(B)</bold> A T<sub>RM</sub> cell marker CD69 downregulates the expression of S1PR1, which is a receptor required for tissue egress. The expression of transcription factor KLF-2, which upregulates S1PR1 expression, is downregulated in T<sub>RM</sub> cells (<xref ref-type="bibr" rid="B6">6</xref>). CD103 and CD49a are parts of the integrins &#x3b1;E&#x3b2;7 and &#x3b1;1&#x3b2;1, respectively. CD103 interacts with E-cadherin on epithelial cells, whereas CD49a binds to collagen IV (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B7">7</xref>). Almost all renal T<sub>RM</sub> cells express the chemokine receptor CXCR3 and, to a lower degree, CXCR6 (<xref ref-type="bibr" rid="B8">8</xref>). Inhibitory receptors, especially PD-1, are commonly expressed on T<sub>RM</sub> cells compared with circulating memory T cells. IL-15 and TGF-&#x3b2; are required to induce and maintain renal T<sub>RM</sub> cells in mice (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Created with <uri xlink:href="https://BioRender.com">BioRender.com</uri>
</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1111521-g001.tif"/>
</fig>
<p>Glomerulonephritis (GN) is a group of immune-mediated kidney diseases, either in the context of systemic or kidney-specific autoimmune disorders, and lead to the damage of the glomeruli and other compartments of the kidney (<xref ref-type="bibr" rid="B18">18</xref>). The most severe form is crescentic GN (cGN) or rapid-progressive glomerulonephritis (RPGN), which is mainly observed in autoimmune kidney diseases such as lupus nephritis (LN) and ANCA-associated GN. The histopathological features of cGN are multilayered cells in the Bowman&#x2019;s capsule due to epithelial hyperplasia (crescents) and infiltration of various immune cells in the periglomerular area (<xref ref-type="bibr" rid="B19">19</xref>). Importantly, T cells are one of the most abundant immune cell populations in the inflamed kidney tissue. Most of the renal T cells have a tissue-resident phenotype (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>), and the number of tissue-resident T cells correlates with disease severity (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>). Moreover, recent studies reported that T<sub>RM</sub> cells might be associated with the development and/or relapse of autoimmune diseases (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B26">26</xref>). For these reasons, it is of great importance to summarize and discuss the current understanding of renal T<sub>RM</sub> cells. From the next section, we will shortly explain the current knowledge of T<sub>RM</sub> cells and then discuss the role of T<sub>RM</sub> cells in renal autoimmune diseases.</p>
</sec>
<sec id="s2">
<title>General features of T<sub>RM</sub> cells</title>
<p>T<sub>RM</sub> cells are particularly characterized by two features &#x2013; tissue residency and longevity &#x2013; which are identified by distinct surface markers and transcriptional profiles (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B27">27</xref>). Similar to other non-lymphoid organs, tissue-residency of renal T<sub>RM</sub> cells is mainly assessed by the expression of CD69 and resident-integrins such as CD103 and CD49a, and the downregulation of transcription factor KLF-2, all of which contribute to preventing tissue egress of T<sub>RM</sub> cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1B</bold>
</xref>) (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B28">28</xref>). The longevity of T<sub>RM</sub> cells is mainly regulated by a transcriptional network which enables adaptation to a certain tissue environment with a constant supply of cytokines and nutrients. Mice studies showed that IL-15 and TGF-&#x3b2; are important for the development and survival of renal T<sub>RM</sub> cells after viral infection (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B29">29</xref>). Regarding nutrition, T<sub>RM</sub> cells in the skin utilize exogenous free fatty acids (FFA) for oxidative phosphorylation (OXPHOS) to generate ATP (<xref ref-type="bibr" rid="B30">30</xref>). Given that the human kidney is a highly hypoxic organ, which might inhibit efficient OXPHOS (<xref ref-type="bibr" rid="B31">31</xref>), further tissue-specific analysis is crucial to determine the FFA-dependency of renal T<sub>RM</sub> cells.</p>
<p>T<sub>RM</sub> cells can be both protective and pathogenic. In the skin, pathogen- or sterile inflammation-triggered T<sub>RM</sub> cells show protective properties leading to enhanced pathogen clearance upon antigen re-encounter (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). On the other hand, auto-antigen specific T<sub>RM</sub> cells can be constantly exposed to self-antigens, contributing to chronic inflammation in autoimmune skin diseases (<xref ref-type="bibr" rid="B34">34</xref>). Because of the emerging pathophysiological role in relapsing autoimmune skin diseases, T<sub>RM</sub> cells have been attracting attention in the field of nephrology as well (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B26">26</xref>). In human kidneys, the presence of T<sub>RM</sub> cells specific to systemic virus infections (Epstein-Barr virus, cytomegalovirus, influenza A, and BK virus) has been reported (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B14">14</xref>), although their functional relevance such as accelerated host defense still needs to be clarified.</p>
</sec>
<sec id="s3">
<title>T<sub>RM</sub> cells in lupus nephritis</title>
<p>Systemic lupus erythematosus (SLE) is a systemic and chronic autoimmune disease, which typically manifests in several organs and tissues. The etiology of SLE is still not fully understood, but genetic susceptibility, environmental influences, hormones, and dysregulation of the innate and adaptive immune system have been implicated (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). In SLE, up to 50% of patients develop LN (<xref ref-type="bibr" rid="B37">37</xref>). The main pathophysiological driver of renal tissue injury is the loss of self-tolerance, which leads to the production of autoantibodies against nuclear antigens and the accumulation of immune complexes within the glomeruli (<xref ref-type="bibr" rid="B38">38</xref>). These immune complexes activate the complement system, inducing a massive tissue infiltration of immune cells.</p>
<p>T cells are the most abundant immune cells in biopsies of patients suffering from LN as well as in lupus-prone mice kidneys (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B40">40</xref>). T cells localize mainly in the interstitial and periglomerular regions in LN biopsies (<xref ref-type="bibr" rid="B39">39</xref>&#x2013;<xref ref-type="bibr" rid="B41">41</xref>). Depletion of infiltrating T cells by antibody injection into MRL/lpr mice significantly reduced renal inflammation and tissue damage, underlining the pathophysiologic role of T cells in LN. Furthermore, T cell infiltration correlates with clinical parameters such as proteinuria, serum creatinine levels, and histopathological grading (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>).</p>
<p>Flow cytometric analyses of human LN biopsies and MRL/lpr mice revealed that most of the kidney-infiltrating T cells have T<sub>RM</sub> cell phenotype, such as the expression of CD69 and/or CD103. In addition, the numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>RM</sub> cells in LN kidney are significantly higher compared with healthy control tissue (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). Recent studies using scRNA-seq determined the immune cell composition and transcription profiles of the kidney-infiltrating immune cells during LN (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B42">42</xref>). The analysis of human LN biopsies revealed the presence of different T cell clusters in the kidney and showed that feature genes of CD8<sup>+</sup> T<sub>RM</sub> cells include <italic>ZNF683</italic> (HOBIT), <italic>ITGAE</italic>, <italic>ITGA1</italic>, and <italic>XCL1</italic> (<xref ref-type="bibr" rid="B26">26</xref>).</p>
<p>Renal T<sub>RM</sub> cells in LN might have enhanced effector functions. CD8<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub> cells from MRL/lpr mice kidneys showed the superior production of cytokines and cytotoxic molecules, such as TNF-&#x3b1;, IFN-&#x3b3;, perforin, and granzyme B, in comparison to CD103<sup>-</sup> non-T<sub>RM</sub> cells (<xref ref-type="bibr" rid="B20">20</xref>). However, another study revealed contrasting results, showing an impaired cytokine production in association with the expression of inhibitory receptors, such as PD-1 and Tim3, which are generally observed during T cell exhaustion (<xref ref-type="bibr" rid="B21">21</xref>). A scRNA-seq analysis of the murine lupus model showed an exhaustion signature in both CD4<sup>+</sup> and CD8<sup>+</sup> renal T cells, suggesting that kidney-infiltrating T cells gradually develop T cell exhaustion (<xref ref-type="bibr" rid="B42">42</xref>). Trajectory analyses revealed that CD4<sup>+</sup> and CD8<sup>+</sup> T cells might go through several developmental stages. They first exhibit effector functions during migration to the tissue, and then upregulate hypoxia-inducible genes which finally lead to the T cell exhaustion (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>T cell clonality analysis is of great importance for better understanding adaptive immunity in health and disease. In autoimmune diseases, autoreactive T cells clonally expand and accumulate in inflamed organs (<xref ref-type="bibr" rid="B44">44</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>). TCR &#xdf;-chain sequencing combined with laser-capture microdissection from kidney biopsies revealed the predominance of clonally expanded CD4<sup>+</sup> and CD8<sup>+</sup> T cells in periglomerular regions, suggesting both T cells play roles in the progression of LN (<xref ref-type="bibr" rid="B46">46</xref>). In addition, a recent study reported that the frequency of nuclear antigen-reactive CD4<sup>+</sup> T cells correlated with disease severity (<xref ref-type="bibr" rid="B47">47</xref>). This study revealed the presence of CD4<sup>+</sup> T cells specific to canonical nuclear antigens SmD1, RNP70, histone, Ro, and La in patients with LN.</p>
<p>During kidney inflammation, leukocytes including T cells can be found in the urine (<xref ref-type="bibr" rid="B48">48</xref>&#x2013;<xref ref-type="bibr" rid="B50">50</xref>). Mass cytometry analysis of urinary T cells from LN patients revealed the expression of CD69, indicating that even T cells with a tissue-resident phenotype can be observed in the urine (<xref ref-type="bibr" rid="B50">50</xref>). Furthermore, the amount of T cells in the urine correlates with disease activity as well as severity, thus can be used as a biomarker in LN (<xref ref-type="bibr" rid="B49">49</xref>). Interestingly, nuclear antigen-reactive T cells are enriched in the urine of LN patients compared with the blood. This indicates that urinary T cells might, to some extent, reflect T cell clonality in the inflamed kidney tissue during LN (<xref ref-type="bibr" rid="B47">47</xref>).</p>
</sec>
<sec id="s4">
<title>T<sub>RM</sub> cells in ANCA-associated GN</title>
<p>ANCA-associated vasculitis (AAV) is a group of autoimmune diseases affecting small-sized vessels, encompassing microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) (<xref ref-type="bibr" rid="B51">51</xref>&#x2013;<xref ref-type="bibr" rid="B53">53</xref>). Similar to SLE, the etiology of AAV is still not fully understood, but generally considered to be the result of multiple factors, including genetic susceptibility (e.g., MHC II genotypes) and environmental factors, such as pathogens and drugs (<xref ref-type="bibr" rid="B54">54</xref>&#x2013;<xref ref-type="bibr" rid="B57">57</xref>). All AAV can affect the kidney and induce cGN. Each disease is commonly characterized by auto-antibodies directed against specific antigens, namely myeloperoxidase (MPO) and proteinase 3 (PR3). In general, MPO-ANCA is common in MPA, whereas PR3-ANCA is associated with GPA. Both antigens are proteins located within neutrophils and are unleashed from the cells following activation (<xref ref-type="bibr" rid="B53">53</xref>). Upon bacterial infections, neutrophils are activated by pro-inflammatory cytokines as well as direct contact with the pathogen, and initiate neutrophil extracellular traps (NETs) formation. Under physiological circumstances, NETs are cleared in a timely manner by specific enzymes, such as DNase I. In AAV patients, the degradation of NETs is impaired, leading to the persistent NET formation and disrupted tolerance to auto-antigens, such as MPO and PR3, resulting in the production of auto-antibodies MPO- and PR3-ANCA. ANCAs bind to neutrophils, leading to changes in adhesion molecule expression, the release of reactive oxygen species, cytokines, and lytic enzymes, and eventually induction of necrotizing vasculitis (<xref ref-type="bibr" rid="B58">58</xref>).</p>
<p>In ANCA-associated GN, the accumulation of T cells in the inflamed kidney tissue is observed (<xref ref-type="bibr" rid="B59">59</xref>). The number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells correlates with kidney function. Furthermore, in the glomeruli with segmental necrosis and cellular crescents, active glomerular lesions correlate with intraglomerular T cells (<xref ref-type="bibr" rid="B59">59</xref>). In AAV patients, MPO- and PR3-specific CD4<sup>+</sup> T cells were identified, showing a decreased TCR diversity and clonal expansion (<xref ref-type="bibr" rid="B55">55</xref>&#x2013;<xref ref-type="bibr" rid="B57">57</xref>). These autoreactive T cells show memory T cell phenotype and secrete proinflammatory cytokines including IL-17A (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>A scRNA-seq analysis of T cells from ANCA-associated GN biopsies showed a variety of T cell populations in the inflamed kidney tissue. Those T cells include CD4<sup>+</sup> T<sub>RM</sub> cells with different transcriptome profiles, such as type1 or typ3 immunity-associated gene expression (<xref ref-type="bibr" rid="B17">17</xref>). The number of CD69<sup>+</sup> T<sub>RM</sub> cells was significantly higher in ANCA-associated GN biopsies compared to healthy renal tissue, indicating the recruitment of autoreactive T cells into the kidneys of patients (<xref ref-type="bibr" rid="B17">17</xref>). As observed in LN, the abundance of T<sub>RM</sub> cells positively correlated with disease activity. The T<sub>RM</sub> cells from ANCA-associated GN showed an upregulation of genes involved in T cell proliferation, activation, and cytokine signaling compared with healthy control (<xref ref-type="bibr" rid="B17">17</xref>).</p>
<p>While antigen-specific immunity is the central function of T cells, TCR-independent activation (bystander T cell activation) has also been reported (<xref ref-type="bibr" rid="B61">61</xref>). Upon activation by cytokines, bystander T cells can immediately secrete effector cytokines in the absence of antigen stimulation. This finding suggests that the induction of renal T<sub>RM</sub> cells can be harmful to the kidney tissue regardless of the antigen-specificity. In mice studies, systemic infection of <italic>Staphylococcus aureus</italic> or <italic>Candida albicans</italic> induced renal CD4<sup>+</sup> T<sub>RM</sub> cells including T<sub>RM</sub>17 cells, which secrete IL-17A upon reactivation. The presence of T<sub>RM</sub> cells significantly aggravated the progression of experimental GN, indicating that bystander T<sub>RM</sub> cells contributed to GN independent of TCR signaling. <italic>In vitro</italic> study revealed that T<sub>RM</sub> cells can be activated in the presence of a cytokine cocktail of IL-23, IL-6, and IL-1&#x3b2; (<xref ref-type="bibr" rid="B17">17</xref>). Therefore, future analysis should focus on not only autoreactive T cells but also activated bystander T cells in autoimmune kidney diseases.</p>
</sec>
<sec id="s5">
<title>Treatment strategies for renal autoimmune diseases</title>
<p>After diagnosing kidney involvement in systemic autoimmune diseases such as SLE and AAV, therapeutic intervention is needed to prevent progressive kidney injury. In general, therapy can be divided into two phases &#x2013; induction therapy to rapidly suppress inflammation and maintenance therapy to prevent relapse. Current treatment strategies are largely based on systemic immunosuppressants (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Simplified treatment strategies in LN and ANCA-associated GN (esp. active, severe GPA/MPA) (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">LN</th>
<th valign="top" align="center">ANCA-associated GN</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Induction therapy</td>
<td valign="top" align="left">Hydroxychloroquine (basic therapy) +<break/>Glucocorticoids + Mycophenolate mofetil + Cyclophosphamide</td>
<td valign="top" align="left">Glucocorticoids +<break/>Rituximab or Cyclophosphamide<break/>(Plasma exchange)</td>
</tr>
<tr>
<td valign="top" align="left">Maintenance therapy</td>
<td valign="top" align="left">Hydroxychloroquine (basic therapy) +<break/>Mycophenolate mofetil or Azathioprine</td>
<td valign="top" align="left">Rituximab or<break/>Azathioprine</td>
</tr>
<tr>
<td valign="top" align="left">Add-On</td>
<td valign="top" align="left">Renin-angiotensin-aldosterone system blockers<break/>Belimumab<break/>(SGLT2 inhibitors)</td>
<td valign="top" align="left">Renin-angiotensin-aldosterone system blockers<break/>Mycophenolate mofetil<break/>Avacopan<break/>(SGLT2 inhibitors)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Generally, the therapy regimen depends on disease severity and the risk of progression. Moreover, the therapy regimen changes according to the type of ANCA-associated GN.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Some therapeutic strategies for LN or ANCA-associated GN target B cells and/or plasma cells. The number of autoantibody-producing cells can be reduced by using rituximab, belimumab, or daratumumab, which are monoclonal antibodies against CD20, B-cell activating factor (BAFF), or CD38, respectively (<xref ref-type="bibr" rid="B63">63</xref>&#x2013;<xref ref-type="bibr" rid="B65">65</xref>). In ANCA-associated GN, the complement pathway can also be targeted. Avacopan, an orally available C5a receptor antagonist which blocks neutrophil chemoattraction and activation, is noninferior to prednisone taper with respect to remission and shows better eGFR recovery (<xref ref-type="bibr" rid="B3">3</xref>). Despite the therapeutic progress, efficient treatment strategy targeting T cells has not been established.</p>
<p>Recent studies suggested that T<sub>RM</sub> cells can be targeted by diverse strategies. Firstly, T<sub>RM</sub> cell-specific metabolic pathways can be modulated. T<sub>RM</sub> cells require exogenous FFA uptake for their survival and function, and T cell-specific deletion of FABP4/5 impairs the development and function of T<sub>RM</sub> cells (<xref ref-type="bibr" rid="B30">30</xref>). Therefore, inhibiting FFA uptake can be an efficient treatment strategy targeting T<sub>RM</sub> cells. However, FFA-dependency and general metabolic pathways of renal T<sub>RM</sub> cells still need to be determined. Secondly, cytokines essential for long-term survival of T<sub>RM</sub> cells, e.g., IL-15, can be targeted to reduce the cells (<xref ref-type="bibr" rid="B66">66</xref>). CD122, which is a subunit of IL-15 and IL-2 receptor, is expressed by T<sub>RM</sub> cells as well as effector T cells (<xref ref-type="bibr" rid="B67">67</xref>). In vitiligo, an autoimmune disease affecting the skin, the number of T<sub>RM</sub> cells was successfully reduced by an anti-CD122 antibody therapy (<xref ref-type="bibr" rid="B67">67</xref>). Short-term treatment with the anti-CD122 therapy inhibited the production of cytokine by T<sub>RM</sub> cells, and long-term treatment depleted T<sub>RM</sub> cells from skin lesions. Given CD122 is expressed by T<sub>RM</sub> cells in different organs, the anti-CD122 therapy might be effective for renal T<sub>RM</sub> cells as well. Moreover, downstream of IL-15 and CD122, such as JAK-STAT pathways, can be blocked. Tofacitinib, an inhibitor of JAK1 and JAK3, impaired the survival of renal T<sub>RM</sub> cells, contributing to improved kidney function in MRL/lpr lupus mice model (<xref ref-type="bibr" rid="B20">20</xref>). Thirdly, autoreactive T cell-specific intervention might be possible. Diverse methods are currently under investigation to induce antigen-specific immune tolerance, and the methods include autoantigen-coated microparticles, autoantigen peptide-MHC multimers, and antigen-specific regulatory T cell transfer (<xref ref-type="bibr" rid="B68">68</xref>). In murine models of type I diabetes, multiple sclerosis and arthritis, disease-relevant peptide-MHC class II-nanoparticles successfully reversed established disease in association with systemic expansions of cognate CD4<sup>+</sup> T cells displaying a type 1 regulatory T cell phenotype (<xref ref-type="bibr" rid="B68">68</xref>). Importantly, these peptide-MHC-based nanomedicines could suppress autoimmune diseases without suppressing systemic immunity. In order to develop T<sub>RM</sub> cell-targeting therapeutic strategies, further studies should focus on characterizing renal T<sub>RM</sub> cells and microenvironments in different disease conditions.</p>
</sec>
<sec id="s6" sec-type="conclusions">
<title>Conclusion</title>
<p>The discovery of T<sub>RM</sub> cells has significantly improved our understanding of immunology. Several studies analyzing animal models and patients with renal autoimmune diseases successfully identified CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>RM</sub> cell populations in the kidney and showed potential clinical relevance. Autoreactive T<sub>RM</sub> cells can be clonally expanded due to self-antigen exposure, contributing to autoimmune kidney diseases (<xref ref-type="bibr" rid="B44">44</xref>&#x2013;<xref ref-type="bibr" rid="B46">46</xref>). Of interest, T<sub>RM</sub> cells induced by infections also stay in the kidney and can be activated during autoimmunity (bystander T cell activation) promoting tissue damage (<xref ref-type="bibr" rid="B17">17</xref>). Better characterization of T<sub>RM</sub> cells and microenvironment in renal autoimmune diseases might lead to the development of T<sub>RM</sub> cell-specific therapeutic strategies.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>PG wrote a draft. NA and UP supervised and finalized the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenkel</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Masopust</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Tissue-resident memory T cells</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>41</volume>(<issue>6</issue>):<page-range>886&#x2013;97</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2014.12.007</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asada</surname> <given-names>N</given-names>
</name>
<name>
<surname>Ginsberg</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gagliani</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mittr&#xfc;cker</surname> <given-names>H-W</given-names>
</name>
<name>
<surname>Panzer</surname> <given-names>U</given-names>
</name>
</person-group>. <article-title>Tissue-resident memory T cells in the kidney</article-title>. <source>Semin Immunopathology</source> (<year>2022</year>) <volume>44</volume>(<issue>6</issue>):<page-range>801&#x2013;11</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s00281-022-00927-7</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayne</surname> <given-names>DRW</given-names>
</name>
<name>
<surname>Merkel</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Schall</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Bekker</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Avacopan for the treatment of ANCA-associated vasculitis</article-title>. <source>N Engl J Med</source> (<year>2021</year>) <volume>384</volume>(<issue>7</issue>):<fpage>599</fpage>&#x2013;<lpage>609</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2023386</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banchereau</surname> <given-names>J</given-names>
</name>
<name>
<surname>Steinman</surname> <given-names>RM</given-names>
</name>
</person-group>. <article-title>Dendritic cells and the control of immunity</article-title>. <source>Nature</source> (<year>1998</year>) <volume>392</volume>(<issue>6673</issue>):<page-range>245&#x2013;52</page-range>. doi: <pub-id pub-id-type="doi">10.1038/32588</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dornieden</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sattler</surname> <given-names>A</given-names>
</name>
<name>
<surname>Pascual-Reguant</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ruhm</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Thiel</surname> <given-names>LG</given-names>
</name>
<name>
<surname>Bergmann</surname> <given-names>YS</given-names>
</name>
<etal/>
</person-group>. <article-title>Signatures and specificity of tissue-resident lymphocytes identified in human renal peritumor and tumor tissue</article-title>. <source>J Am Soc Nephrol</source> (<year>2021</year>) <volume>32</volume>(<issue>9</issue>):<page-range>2223&#x2013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2020101528</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Braun</surname> <given-names>A</given-names>
</name>
<name>
<surname>Macleod</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Collins</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tebartz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Bedoui</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention</article-title>. <source>J Immunol</source> (<year>2015</year>) <volume>194</volume>(<issue>5</issue>):<page-range>2059&#x2013;63</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1402256</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>W</given-names>
</name>
<name>
<surname>Bergsbaken</surname> <given-names>T</given-names>
</name>
<name>
<surname>Edelblum</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>The multifunctional nature of CD103 (&#x3b1;E&#x3b2;7 integrin) signaling in tissue-resident lymphocytes</article-title>. <source>Am J Physiol Cell Physiol</source> (<year>2022</year>) <volume>323</volume>(<issue>4</issue>):<fpage>C1161</fpage>&#x2013;<lpage>c1167</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpcell.00338.2022</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Putten</surname> <given-names>C</given-names>
</name>
<name>
<surname>Remmerswaal</surname> <given-names>EBM</given-names>
</name>
<name>
<surname>Terpstra</surname> <given-names>ML</given-names>
</name>
<name>
<surname>van der Bom</surname> <given-names>ND</given-names>
</name>
<name>
<surname>Kers</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ten Berge</surname> <given-names>IJM</given-names>
</name>
<etal/>
</person-group>. <article-title>CD8 and CD4 T cell populations in human kidneys</article-title>. <source>Cells</source> (<year>2021</year>) <volume>10</volume>(<issue>2</issue>):<fpage>288</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10020288</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>S</given-names>
</name>
<name>
<surname>Demel</surname> <given-names>EL</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>TGF-beta controls the formation of kidney-resident T cells via promoting effector T cell extravasation</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>198</volume>(<issue>2</issue>):<page-range>749&#x2013;56</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1601500</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schenkel</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Fraser</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Casey</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Beura</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Pauken</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Vezys</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>IL-15-Independent maintenance of tissue-resident and boosted effector memory CD8 T cells</article-title>. <source>J Immunol</source> (<year>2016</year>) <volume>196</volume>(<issue>9</issue>):<page-range>3920&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1502337</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flores-Mireles</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Walker</surname> <given-names>JN</given-names>
</name>
<name>
<surname>Caparon</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hultgren</surname> <given-names>SJ</given-names>
</name>
</person-group>. <article-title>Urinary tract infections: epidemiology, mechanisms of infection and treatment options</article-title>. <source>Nat Rev Microbiol</source> (<year>2015</year>) <volume>13</volume>(<issue>5</issue>):<page-range>269&#x2013;84</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro3432</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fogo</surname> <given-names>AB</given-names>
</name>
<name>
<surname>Lusco</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Najafian</surname> <given-names>B</given-names>
</name>
<name>
<surname>Alpers</surname> <given-names>CE</given-names>
</name>
</person-group>. <article-title>AJKD atlas of renal pathology: Cytomegalovirus infection</article-title>. <source>Am J Kidney Dis</source> (<year>2016</year>) <volume>68</volume>(<issue>6</issue>):<page-range>e35&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2016.10.008</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badiee</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hashemizadeh</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Opportunistic invasive fungal infections: diagnosis &amp; clinical management</article-title>. <source>Indian J Med Res</source> (<year>2014</year>) <volume>139</volume>(<issue>2</issue>):<fpage>195</fpage>&#x2013;<lpage>204</lpage>.</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parga-Vidal</surname> <given-names>L</given-names>
</name>
<name>
<surname>van Aalderen</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Stark</surname> <given-names>R</given-names>
</name>
<name>
<surname>van Gisbergen</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Tissue-resident memory T cells in the urogenital tract</article-title>. <source>Nat Rev Nephrol</source> (<year>2022</year>) <volume>18</volume>(<issue>4</issue>):<page-range>209&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41581-021-00525-0</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stewart</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Ferdinand</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Young</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Mitchell</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Loudon</surname> <given-names>KW</given-names>
</name>
<name>
<surname>Riding</surname> <given-names>AM</given-names>
</name>
<etal/>
</person-group>. <article-title>Spatiotemporal immune zonation of the human kidney</article-title>. <source>Science</source> (<year>2019</year>) <volume>365</volume>(<issue>6460</issue>):<page-range>1461&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.aat5031</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Na</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Park</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>DK</given-names>
</name>
<etal/>
</person-group>. <article-title>Immune cell composition in normal human kidneys</article-title>. <source>Sci Rep</source> (<year>2020</year>) <volume>10</volume>(<issue>1</issue>):<fpage>15678</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-72821-x</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krebs</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Reimers</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Paust</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Bartsch</surname> <given-names>P</given-names>
</name>
<name>
<surname>Nu&#xf1;ez</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Pathogen-induced tissue-resident memory T(H)17 (T(RM)17) cells amplify autoimmune kidney disease</article-title>. <source>Sci Immunol</source> (<year>2020</year>) <volume>5</volume>(<issue>50</issue>):<elocation-id>eaba4163</elocation-id>. doi: <pub-id pub-id-type="doi">10.1126/sciimmunol.aba4163</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linke</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tiegs</surname> <given-names>G</given-names>
</name>
<name>
<surname>Neumann</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Pathogenic T-cell responses in immune-mediated glomerulonephritis</article-title>. <source>Cells</source> (<year>2022</year>) <volume>11</volume>(<issue>10</issue>):<fpage>1625</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells11101625</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smeets</surname> <given-names>B</given-names>
</name>
<name>
<surname>Uhlig</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fuss</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mooren</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wetzels</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Floege</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells</article-title>. <source>J Am Soc Nephrol</source> (<year>2009</year>) <volume>20</volume>(<issue>12</issue>):<page-range>2604&#x2013;15</page-range>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2009010122</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>JAK/STAT signaling controls the fate of CD8(+)CD103(+) tissue-resident memory T cell in lupus nephritis</article-title>. <source>J Autoimmun</source> (<year>2020</year>) <volume>109</volume>:<fpage>102424</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaut.2020.102424</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tilstra</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Avery</surname> <given-names>L</given-names>
</name>
<name>
<surname>Menk</surname> <given-names>AV</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Smita</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kane</surname> <given-names>LP</given-names>
</name>
<etal/>
</person-group>. <article-title>Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted</article-title>. <source>J Clin Invest</source> (<year>2018</year>) <volume>128</volume>(<issue>11</issue>):<page-range>4884&#x2013;97</page-range>. doi: <pub-id pub-id-type="doi">10.1172/JCI120859</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jabs</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Burek</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Kuppers</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>B</given-names>
</name>
<name>
<surname>Prendergast</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice</article-title>. <source>Cell Immunol</source> (<year>1992</year>) <volume>141</volume>(<issue>2</issue>):<fpage>496</fpage>&#x2013;<lpage>507</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0008-8749(92)90166-M</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jevnikar</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Grusby</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Glimcher</surname> <given-names>LH</given-names>
</name>
</person-group>. <article-title>Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice</article-title>. <source>J Exp Med</source> (<year>1994</year>) <volume>179</volume>(<issue>4</issue>):<page-range>1137&#x2013;43</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.179.4.1137</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merino</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fossati</surname> <given-names>L</given-names>
</name>
<name>
<surname>Iwamoto</surname> <given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lemoine</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ibnou-Zekri</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of long-term anti-CD4 or anti-CD8 treatment on the development of lpr CD4- CD8- double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice</article-title>. <source>J Autoimmun</source> (<year>1995</year>) <volume>8</volume>(<issue>1</issue>):<fpage>33</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1006/jaut.1995.0003</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su&#xe1;rez-Fueyo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Bradley</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Tsokos</surname> <given-names>GC</given-names>
</name>
</person-group>. <article-title>T Cells in systemic lupus erythematosus</article-title>. <source>Curr Opin Immunol</source> (<year>2016</year>) <volume>43</volume>:<page-range>32&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.coi.2016.09.001</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arazi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rao</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Berthier</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Davidson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hoover</surname> <given-names>PJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The immune cell landscape in kidneys of patients with lupus nephritis</article-title>. <source>Nat Immunol</source> (<year>2019</year>) <volume>20</volume>(<issue>7</issue>):<page-range>902&#x2013;14</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-019-0398-x</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Mackay</surname> <given-names>LK</given-names>
</name>
</person-group>. <article-title>Tissue-resident memory T cells: local specialists in immune defence</article-title>. <source>Nat Rev Immunol</source> (<year>2016</year>) <volume>16</volume>(<issue>2</issue>):<fpage>79</fpage>&#x2013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri.2015.3</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlson</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Endrizzi</surname> <given-names>BT</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>X</given-names>
</name>
<name>
<surname>Weinreich</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Walsh</surname> <given-names>ER</given-names>
</name>
<etal/>
</person-group>. <article-title>Kruppel-like factor 2 regulates thymocyte and T-cell migration</article-title>. <source>Nature</source> (<year>2006</year>) <volume>442</volume>(<issue>7100</issue>):<fpage>299</fpage>&#x2013;<lpage>302</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature04882</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Rahimpour</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>JZ</given-names>
</name>
<name>
<surname>Collins</surname> <given-names>N</given-names>
</name>
<name>
<surname>Stock</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Hafon</surname> <given-names>ML</given-names>
</name>
<etal/>
</person-group>. <article-title>The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin</article-title>. <source>Nat Immunol</source> (<year>2013</year>) <volume>14</volume>(<issue>12</issue>):<page-range>1294&#x2013;301</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.2744</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>T</given-names>
</name>
<name>
<surname>Park</surname> <given-names>CO</given-names>
</name>
<name>
<surname>Lofftus</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Mei</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism</article-title>. <source>Nature</source> (<year>2017</year>) <volume>543</volume>(<issue>7644</issue>):<page-range>252&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature21379</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname> <given-names>CT</given-names>
</name>
<name>
<surname>Scholz</surname> <given-names>CC</given-names>
</name>
</person-group>. <article-title>The effect of HIF on metabolism and immunity</article-title>. <source>Nat Rev Nephrol</source> (<year>2022</year>) <volume>18</volume>(<issue>9</issue>):<page-range>573&#x2013;87</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41581-022-00587-8</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackay</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Stock</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>JZ</given-names>
</name>
<name>
<surname>Jones</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Kent</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Mueller</surname> <given-names>SN</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2012</year>) <volume>109</volume>(<issue>18</issue>):<page-range>7037&#x2013;42</page-range>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1202288109</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gebhardt</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wakim</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Eidsmo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Reading</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Heath</surname> <given-names>WR</given-names>
</name>
<name>
<surname>Carbone</surname> <given-names>FR</given-names>
</name>
</person-group>. <article-title>Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus</article-title>. <source>Nat Immunol</source> (<year>2009</year>) <volume>10</volume>(<issue>5</issue>):<page-range>524&#x2013;30</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.1718</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Owczarczyk Saczonek</surname> <given-names>A</given-names>
</name>
<name>
<surname>Krajewska-W&#x142;odarczyk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kasprowicz-Furma&#x144;czyk</surname> <given-names>M</given-names>
</name>
<name>
<surname>Placek</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Immunological memory of psoriatic lesions</article-title>. <source>Int J Mol Sci</source> (<year>2020</year>) <volume>21</volume>(<issue>2</issue>):<fpage>625</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21020625</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisnevskaia</surname> <given-names>L</given-names>
</name>
<name>
<surname>Murphy</surname> <given-names>G</given-names>
</name>
<name>
<surname>Isenberg</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>Lancet</source> (<year>9957</year>) <volume>2014</volume>:<page-range>1878&#x2013;88</page-range>:<fpage>384</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60128-8</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsokos</surname> <given-names>GC</given-names>
</name>
</person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> (<year>2011</year>) <volume>365</volume>(<issue>22</issue>):<page-range>2110&#x2013;21</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra1100359</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parikh</surname> <given-names>SV</given-names>
</name>
<name>
<surname>Almaani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Brodsky</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rovin</surname> <given-names>BH</given-names>
</name>
</person-group>. <article-title>Update on lupus nephritis: Core curriculum 2020</article-title>. <source>Am J Kidney Dis</source> (<year>2020</year>) <volume>76</volume>(<issue>2</issue>):<page-range>265&#x2013;81</page-range>. doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2019.10.017</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lech</surname> <given-names>M</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>HJ</given-names>
</name>
</person-group>. <article-title>The pathogenesis of lupus nephritis</article-title>. <source>J Am Soc Nephrol</source> (<year>2013</year>) <volume>24</volume>(<issue>9</issue>):<page-range>1357&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2013010026</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexopoulos</surname> <given-names>E</given-names>
</name>
<name>
<surname>Seron</surname> <given-names>D</given-names>
</name>
<name>
<surname>Hartley</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Cameron</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>Lupus nephritis: correlation of interstitial cells with glomerular function</article-title>. <source>Kidney Int</source> (<year>1990</year>) <volume>37</volume>(<issue>1</issue>):<page-range>100&#x2013;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ki.1990.14</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Couzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Merville</surname> <given-names>P</given-names>
</name>
<name>
<surname>Demini&#xe8;re</surname> <given-names>C</given-names>
</name>
<name>
<surname>Moreau</surname> <given-names>JF</given-names>
</name>
<name>
<surname>Combe</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pellegrin</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis</article-title>. <source>Arthritis Rheum</source> (<year>2007</year>) <volume>56</volume>(<issue>7</issue>):<page-range>2362&#x2013;70</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.22654</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Association between tubulointerstitial CD8+T cells and renal prognosis in lupus nephritis</article-title>. <source>Int Immunopharmacol</source> (<year>2021</year>) <volume>99</volume>:<fpage>107877</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.intimp.2021.107877</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smita</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chikina</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shlomchik</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Tilstra</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>Heterogeneity and clonality of kidney-infiltrating T cells in murine lupus nephritis</article-title>. <source>JCI Insight</source> (<year>2022</year>) <volume>7</volume>(<issue>8</issue>):<elocation-id>e156048</elocation-id>. doi: <pub-id pub-id-type="doi">10.1172/jci.insight.156048</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugahara</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nangaku</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Hypoxia-inducible factor and oxygen biology in the kidney</article-title>. <source>Kidney360</source> (<year>2020</year>) <volume>1</volume>(<issue>9</issue>):<page-range>1021&#x2013;31</page-range>. doi: <pub-id pub-id-type="doi">10.34067/KID.0001302020</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Matsumura</surname> <given-names>R</given-names>
</name>
<name>
<surname>Koyama</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sugiyama</surname> <given-names>T</given-names>
</name>
<name>
<surname>Sueishi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shibuya</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>T Cell receptor repertoire of T cells in the kidneys of patients with lupus nephritis</article-title>. <source>Arthritis Rheum</source> (<year>2002</year>) <volume>46</volume>(<issue>8</issue>):<page-range>2141&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.10432</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Massengill</surname> <given-names>SF</given-names>
</name>
<name>
<surname>Goodenow</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Sleasman</surname> <given-names>JW</given-names>
</name>
</person-group>. <article-title>SLE nephritis is associated with an oligoclonal expansion of intrarenal T cells</article-title>. <source>Am J Kidney Dis</source> (<year>1998</year>) <volume>31</volume>(<issue>3</issue>):<page-range>418&#x2013;26</page-range>. doi: <pub-id pub-id-type="doi">10.1053/ajkd.1998.v31.pm9506678</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winchester</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wiesendanger</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>HZ</given-names>
</name>
<name>
<surname>Steshenko</surname> <given-names>V</given-names>
</name>
<name>
<surname>Peterson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Geraldino-Pardilla</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunologic characteristics of intrarenal T cells: trafficking of expanded CD8+ T cell beta-chain clonotypes in progressive lupus nephritis</article-title>. <source>Arthritis Rheum</source> (<year>2012</year>) <volume>64</volume>(<issue>5</issue>):<page-range>1589&#x2013;600</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.33488</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abdirama</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tesch</surname> <given-names>S</given-names>
</name>
<name>
<surname>Grie&#xdf;bach</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Spee-Mayer von</surname> <given-names>C</given-names>
</name>
<name>
<surname>Humrich</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Stervbo</surname> <given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Nuclear antigen-reactive CD4(+) T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys</article-title>. <source>Kidney Int</source> (<year>2021</year>) <volume>99</volume>(<issue>1</issue>):<page-range>238&#x2013;46</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.kint.2020.05.051</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolff</surname> <given-names>S</given-names>
</name>
<name>
<surname>Abdulahad</surname> <given-names>WH</given-names>
</name>
<name>
<surname>Dijk van</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Limburg</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Kallenberg</surname> <given-names>CG</given-names>
</name>
<name>
<surname>Bijl</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Urinary T cells in active lupus nephritis show an effector memory phenotype</article-title>. <source>Ann Rheum Dis</source> (<year>2010</year>) <volume>69</volume>(<issue>11</issue>):<page-range>2034&#x2013;41</page-range>. doi: <pub-id pub-id-type="doi">10.1136/ard.2009.124636</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Enghard</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rieder</surname> <given-names>C</given-names>
</name>
<name>
<surname>Kopetschke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Klocke</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Undeutsch</surname> <given-names>R</given-names>
</name>
<name>
<surname>Biesen</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response</article-title>. <source>Ann Rheum Dis</source> (<year>2014</year>) <volume>73</volume>(<issue>1</issue>):<page-range>277&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2012-202784</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bertolo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Baumgart</surname> <given-names>S</given-names>
</name>
<name>
<surname>Durek</surname> <given-names>P</given-names>
</name>
<name>
<surname>Peddinghaus</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mei</surname> <given-names>H</given-names>
</name>
<name>
<surname>Rose</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Deep phenotyping of urinary leukocytes by mass cytometry reveals a leukocyte signature for early and non-invasive prediction of response to treatment in active lupus nephritis</article-title>. <source>Front Immunol</source> (<year>2020</year>) <volume>11</volume>:<elocation-id>256</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.00256</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geetha</surname> <given-names>D</given-names>
</name>
<name>
<surname>Jefferson</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>ANCA-associated vasculitis: Core curriculum 2020</article-title>. <source>Am J Kidney Dis</source> (<year>2020</year>) <volume>75</volume>(<issue>1</issue>):<page-range>124&#x2013;37</page-range>. doi: <pub-id pub-id-type="doi">10.1053/j.ajkd.2019.04.031</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jennette</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Falk</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Bacon</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Cid</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Ferrario</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>2012 revised international chapel hill consensus conference nomenclature of vasculitides</article-title>. <source>Arthritis Rheum</source> (<year>2013</year>) <volume>65</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1002/art.37715</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kitching</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Basu</surname> <given-names>N</given-names>
</name>
<name>
<surname>Brouwer</surname> <given-names>E</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jayne</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>ANCA-associated vasculitis</article-title>. <source>Nat Rev Dis Primers</source> (<year>2020</year>) <volume>6</volume>(<issue>1</issue>):<fpage>71</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41572-020-0204-y</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merkel</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>G</given-names>
</name>
<name>
<surname>Monach</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ciavatta</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Byun</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis</article-title>. <source>Arthritis Rheumatol</source> (<year>2017</year>) <volume>69</volume>(<issue>5</issue>):<page-range>1054&#x2013;66</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.40034</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Free</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Stember</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Hess</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>McInnis</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Lardinois</surname> <given-names>O</given-names>
</name>
<name>
<surname>Hogan</surname> <given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis</article-title>. <source>J Autoimmun</source> (<year>2020</year>) <volume>106</volume>:<fpage>102306</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaut.2019.102306</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>DP</given-names>
</name>
<name>
<surname>McInnis</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>EY</given-names>
</name>
<name>
<surname>Stember</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Hogan</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunological interaction of HLA-DPB1 and proteinase 3 in ANCA vasculitis is associated with clinical disease activity</article-title>. <source>J Am Soc Nephrol</source> (<year>2022</year>) <volume>33</volume>(<issue>8</issue>):<page-range>1517&#x2013;27</page-range>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2021081142</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shochet</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kitching</surname> <given-names>AR</given-names>
</name>
</person-group>. <article-title>Identifying antigen-specific T cells in ANCA-associated vasculitis: A glimpse of the future</article-title>? <source>J Am Soc Nephrol</source> (<year>2022</year>) <volume>33</volume>(<issue>8</issue>):<page-range>1435&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2022060668</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakazawa</surname> <given-names>D</given-names>
</name>
<name>
<surname>Masuda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tomaru</surname> <given-names>U</given-names>
</name>
<name>
<surname>Ishizu</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Pathogenesis and therapeutic interventions for ANCA-associated vasculitis</article-title>. <source>Nat Rev Rheumatol</source> (<year>2019</year>) <volume>15</volume>(<issue>2</issue>):<fpage>91</fpage>&#x2013;<lpage>101</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41584-018-0145-y</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O&#x2019;Sullivan</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Summers</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Elgass</surname> <given-names>KD</given-names>
</name>
<name>
<surname>McMillan</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Longano</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis</article-title>. <source>Kidney Int</source> (<year>2015</year>) <volume>88</volume>(<issue>5</issue>):<page-range>1030&#x2013;46</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ki.2015.202</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Disteldorf</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Krebs</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Paust</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Turner</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Nouailles</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tittel</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>CXCL5 drives neutrophil recruitment in TH17-mediated GN</article-title>. <source>J Am Soc Nephrol</source> (<year>2015</year>) <volume>26</volume>(<issue>1</issue>):<fpage>55</fpage>&#x2013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.1681/ASN.2013101061</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>HG</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>MZ</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>Bystander CD4(+) T cells: crossroads between innate and adaptive immunity</article-title>. <source>Exp Mol Med</source> (<year>2020</year>) <volume>52</volume>(<issue>8</issue>):<page-range>1255&#x2013;63</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s12276-020-00486-7</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fanouriakis</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kostopoulou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cheema</surname> <given-names>K</given-names>
</name>
<name>
<surname>Anders</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Aringer</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bajema</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis</article-title>. <source>Ann Rheum Dis</source> (<year>2020</year>) <volume>79</volume>(<issue>6</issue>):<page-range>713&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-216924</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Langford</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Maz</surname> <given-names>M</given-names>
</name>
<name>
<surname>Abril</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gorelik</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guyatt</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>2021 American college of Rheumatology/Vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis</article-title>. <source>Arthritis Rheumatol</source> (<year>2021</year>) <volume>73</volume>(<issue>8</issue>):<page-range>1366&#x2013;83</page-range>. doi: <pub-id pub-id-type="doi">10.1002/art.41773</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Furie</surname> <given-names>R</given-names>
</name>
<name>
<surname>Rovin</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Houssiau</surname> <given-names>F</given-names>
</name>
<name>
<surname>Malvar</surname> <given-names>A</given-names>
</name>
<name>
<surname>Teng</surname> <given-names>YKO</given-names>
</name>
<name>
<surname>Contreras</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Two-year, randomized, controlled trial of belimumab in lupus nephritis</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>383</volume>(<issue>12</issue>):<page-range>1117&#x2013;28</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2001180</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ostendorf</surname> <given-names>L</given-names>
</name>
<name>
<surname>Burns</surname> <given-names>M</given-names>
</name>
<name>
<surname>Durek</surname> <given-names>P</given-names>
</name>
<name>
<surname>Heinz</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Heinrich</surname> <given-names>F</given-names>
</name>
<name>
<surname>Garantziotis</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting CD38 with daratumumab in refractory systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> (<year>2020</year>) <volume>383</volume>(<issue>12</issue>):<page-range>1149&#x2013;55</page-range>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2023325</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Gracht</surname> <given-names>ETI</given-names>
</name>
<name>
<surname>Behr</surname> <given-names>FM</given-names>
</name>
<name>
<surname>Arens</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Functional heterogeneity and therapeutic targeting of tissue-resident memory T cells</article-title>. <source>Cells</source> (<year>2021</year>) <volume>10</volume>(<issue>1</issue>):<fpage>164</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10010164</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richmond</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Strassner</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Zapata</surname> <given-names>L</given-names> <suffix>Jr</suffix>
</name>
<name>
<surname>Garg</surname> <given-names>M</given-names>
</name>
<name>
<surname>Riding</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Refat</surname> <given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo</article-title>. <source>Sci Transl Med</source> (<year>2018</year>) <volume>10</volume>(<issue>450</issue>). doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aam7710</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serra</surname> <given-names>P</given-names>
</name>
<name>
<surname>Santamaria</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Antigen-specific therapeutic approaches for autoimmunity</article-title>. <source>Nat Biotechnol</source> (<year>2019</year>) <volume>37</volume>(<issue>3</issue>):<page-range>238&#x2013;51</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41587-019-0015-4</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>